{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:48:57Z","timestamp":1785408537437,"version":"3.56.0"},"reference-count":44,"publisher":"American Association for Cancer Research (AACR)","issue":"4","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009812","name":"Princess Margaret Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017292","name":"Ovarian Cancer Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017292","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Westaway Ovarian Cancer Research"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>We report a rare case of a young patient (VENUS 167) initially diagnosed with grade 1 endometrioid endometrial cancer, which, following endocrine treatment, presented with mixed aggressive carcinoma with three distinct histologic patterns: grade 1 endometrioid, large cell neuroendocrine, and undifferentiated carcinoma. The surgical specimen at the time of disease progression was used to establish OPTO.85, a patient-derived organoid (PDO), followed by a corresponding organoid-derived xenograft (ODX). Multi-omic analyses confirmed that OPTO.85 accurately reflected the patient\u2019s tumor characteristics. Whole-exome sequencing analysis identified oncogenic alterations in PIK3CA, ARID1A, and CTNNB1. Further RNA sequencing and assay for transposase-accessible chromatin using sequencing analyses revealed enrichment in VEGF and Wnt signaling pathways, suggesting therapeutic vulnerabilities. A high-throughput drug screen was conducted using ApexBio-approved and epigenetic drug libraries, along with kinase inhibitor and tool compound libraries developed at the Ontario Institute of Cancer Research. The OPTO.85 PDO exhibited sensitivity to PI3K inhibitors and responsiveness to VEGF inhibition. Cediranib demonstrated synergy with BKM120, significantly reducing organoid growth. This combination also showed in vivo efficacy in the ODX model, in which dual inhibitors significantly suppressed tumor growth compared with single compounds. This case exemplifies the impact of genomic profiling and patient-derived models in identifying actionable molecular changes in rare cancers with limited therapeutic options and poor prognosis. It highlights that high-throughput sequencing for individual patient tumors and generation of patient-derived models are feasible in endometrial cancer. This preclinical model may assist clinical decision and personalized therapy requiring validation in prospective studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study characterizes a rare aggressive mixed endometrial carcinoma that developed after hormonal therapy. Patient-derived organoid and xenograft models revealed actionable targets in the VEGF and PI3K pathways. Combined cediranib and BKM120 treatment showed synergistic antitumor effects in vitro and in vivo. These findings highlight the potential of integrating molecular profiling and drug testing to guide personalized therapies in rare and recurrent endometrial cancers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0634","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T20:09:41Z","timestamp":1774555781000},"page":"832-841","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8224-7263","authenticated-orcid":false,"given":"Nikolina","family":"Radulovich","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre Ontario Cancer Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network Ontario Cancer Institute, , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6228-1800","authenticated-orcid":false,"given":"Pamela Soberanis","family":"Pina","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre Ontario Cancer Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network Ontario Cancer Institute, , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6439-7826","authenticated-orcid":false,"given":"Molly L.","family":"Udaskin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre Ontario Cancer Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network Ontario Cancer Institute, , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0565-9045","authenticated-orcid":false,"given":"Quan","family":"Li","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre Ontario Cancer Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network Ontario Cancer Institute, , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3645-1159","authenticated-orcid":false,"given":"Kevin C.J.","family":"Nixon","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre Ontario Cancer Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network Ontario Cancer Institute, , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4911-1364","authenticated-orcid":false,"given":"Irene Y.","family":"Xie","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre Ontario Cancer Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network Ontario Cancer Institute, , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7071-5114","authenticated-orcid":false,"given":"Ankita","family":"Nand","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre Ontario Cancer Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network Ontario Cancer Institute, , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0519-3053","authenticated-orcid":false,"given":"Joshua C.","family":"Rosen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre Ontario Cancer Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network Ontario Cancer Institute, , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0295-8648","authenticated-orcid":false,"given":"Ming","family":"Li","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre Ontario Cancer Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network Ontario Cancer Institute, , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4069-2000","authenticated-orcid":false,"given":"Anjelica","family":"Hodgson","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre Ontario Cancer Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network Ontario Cancer Institute, , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3063-0292","authenticated-orcid":false,"given":"Nhu-An","family":"Pham","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre Ontario Cancer Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network Ontario Cancer Institute, , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9510-8641","authenticated-orcid":false,"given":"Amit M.","family":"Oza","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre Ontario Cancer Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network Ontario Cancer Institute, , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0929-9478","authenticated-orcid":false,"given":"Mathieu","family":"Lupien","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre Ontario Cancer Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network Ontario Cancer Institute, , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6024-5558","authenticated-orcid":false,"given":"Robert","family":"Rottapel","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre Ontario Cancer Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network Ontario Cancer Institute, , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9160-5405","authenticated-orcid":false,"given":"Ming-Sound","family":"Tsao","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre Ontario Cancer Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network Ontario Cancer Institute, , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4405-5890","authenticated-orcid":false,"given":"Stephanie","family":"Lheureux","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"publisher"}],"name":"Princess Margaret Cancer Centre Ontario Cancer Institute, , , Toronto, Canada."},{"id":[{"id":"https:\/\/ror.org\/042xt5161","id-type":"ROR","asserted-by":"publisher"}],"name":"University Health Network Ontario Cancer Institute, , , Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"2026041507084599500_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynecol Obstet"},{"key":"2026041507084599500_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"2026041507084599500_bib3","first-page":"387","article-title":"Uncommon morphologic types of endometrial cancer and their mimickers: how much does molecular classification improve the practice for challenging cases?","volume":"14","author":"Saglam","year":"2024","journal-title":"Life (Basel)"},{"key":"2026041507084599500_bib4","doi-asserted-by":"crossref","first-page":"11684","DOI":"10.3390\/ijms231911684","article-title":"TCGA molecular prognostic groups of endometrial carcinoma: current knowledge and future perspectives","volume":"23","author":"Arciuolo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026041507084599500_bib5","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.3802\/jgo.2022.33.e25","article-title":"Treatment and outcomes in undifferentiated and dedifferentiated endometrial carcinoma","volume":"33","author":"Hamilton","year":"2022","journal-title":"J Gynecol Oncol"},{"key":"2026041507084599500_bib6","doi-asserted-by":"crossref","first-page":"e717","DOI":"10.3747\/co.26.5379","article-title":"Inter-laboratory proficiency testing scheme for tumour next-generation sequencing in Ontario: a pilot study","volume":"26","author":"Spence","year":"2019","journal-title":"Curr Oncol"},{"key":"2026041507084599500_bib7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ygyno.2019.09.004","article-title":"Neuroendocrine carcinoma of the endometrium: disease course, treatment, and outcomes","volume":"155","author":"Schlechtweg","year":"2019","journal-title":"Gynecol Oncol"},{"key":"2026041507084599500_bib8","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows\u2013Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"2026041507084599500_bib9","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res"},{"key":"2026041507084599500_bib10","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1101\/gr.129684.111","article-title":"VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing","volume":"22","author":"Koboldt","year":"2012","journal-title":"Genome Res"},{"key":"2026041507084599500_bib11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","article-title":"The Ensembl Variant Effect Predictor","volume":"17","author":"McLaren","year":"2016","journal-title":"Genome Biol"},{"key":"2026041507084599500_bib12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/bioinformatics\/btr670","article-title":"Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data","volume":"28","author":"Boeva","year":"2012","journal-title":"Bioinformatics"},{"key":"2026041507084599500_bib13","doi-asserted-by":"crossref","first-page":"W160","DOI":"10.1093\/nar\/gkw257","article-title":"deepTools2: a next generation web server for deep-sequencing data analysis","volume":"44","author":"Ram\u00edrez","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2026041507084599500_bib14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","article-title":"Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling","volume":"1","author":"Corsello","year":"2020","journal-title":"Nat Cancer"},{"key":"2026041507084599500_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2026041507084599500_bib16","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"FeatureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"2026041507084599500_bib17","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2026041507084599500_bib18","doi-asserted-by":"crossref","first-page":"ELIXIR-709","DOI":"10.12688\/f1000research.24956.2","article-title":"gprofiler2 \u2013 an R package for gene list functional enrichment analysis and namespace conversion toolset g:profiler","volume":"9","author":"Kolberg","year":"2020","journal-title":"F1000Res"},{"key":"2026041507084599500_bib19","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nmeth.4396","article-title":"An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues","volume":"14","author":"Corces","year":"2017","journal-title":"Nat Methods"},{"key":"2026041507084599500_bib20","doi-asserted-by":"crossref","first-page":"11.12.1","DOI":"10.1002\/0471250953.bi1112s47","article-title":"BEDTools: the Swiss-army tool for genome feature analysis","volume":"47","author":"Quinlan","year":"2014","journal-title":"Curr Protoc Bioinformatics"},{"key":"2026041507084599500_bib21","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","article-title":"BEDTools: a flexible suite of utilities for comparing genomic features","volume":"26","author":"Quinlan","year":"2010","journal-title":"Bioinformatics"},{"key":"2026041507084599500_bib22","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/bioinformatics\/btv145","article-title":"ChIP seeker: an R\/Bioconductor package for ChIP peak annotation, comparison and visualization","volume":"31","author":"Yu","year":"2015","journal-title":"Bioinformatics"},{"key":"2026041507084599500_bib23","first-page":"3269","article-title":"Wortmannin inhibits PKB\/Akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice","volume":"7","author":"Ng","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2026041507084599500_bib24","doi-asserted-by":"crossref","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the arrive guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLoS Biol"},{"key":"2026041507084599500_bib25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"2026041507084599500_bib26","doi-asserted-by":"crossref","first-page":"101429","DOI":"10.1016\/j.gore.2024.101429","article-title":"Endometrial large cell neuroendocrine carcinoma: a case report and literature review","volume":"54","author":"Yang","year":"2024","journal-title":"Gynecol Oncol Rep"},{"key":"2026041507084599500_bib27","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"key":"2026041507084599500_bib28","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.3390\/jcm12196373","article-title":"Mixed endometrial epithelial carcinoma: epidemiology, treatment and survival rates\u2014a 10-year retrospective cohort study from a single institution","volume":"12","author":"Pappa","year":"2023","journal-title":"J Clin Med"},{"key":"2026041507084599500_bib29","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3390\/jcm11051461","article-title":"Large cell neuroendocrine carcinoma of the lung: current understanding and challenges","volume":"11","author":"Andrini","year":"2022","journal-title":"J Clin Med"},{"key":"2026041507084599500_bib30","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/ijgc-2019-000504","article-title":"Updates and management algorithm for neuroendocrine tumors of the uterine cervix","volume":"29","author":"Salvo","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"2026041507084599500_bib31","first-page":"1","article-title":"Therapeutic targets and opportunities in endometrial cancer: update on endocrine therapy and nonimmunotherapy targeted options","volume":"40","author":"MacKay","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026041507084599500_bib32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ygyno.2015.07.018","article-title":"A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology\/Gynecologic Oncology Group study","volume":"138","author":"Bender","year":"2015","journal-title":"Gynecol Oncol"},{"key":"2026041507084599500_bib33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2024.02.029","article-title":"Alpelisib for PIK3CA-mutated advanced gynecological cancers: first clues of clinical activity","volume":"183","author":"Passarelli","year":"2024","journal-title":"Gynecol Oncol"},{"key":"2026041507084599500_bib34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/bjc.2016.430","article-title":"Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group","volume":"116","author":"Heudel","year":"2017","journal-title":"Br J Cancer"},{"key":"2026041507084599500_bib35","first-page":"197","article-title":"Effects of intrahippocampal delta-receptors on inhibition of electroconvulsive shock by electro-acupuncture","volume":"10","author":"He","year":"1989","journal-title":"Acta Pharmacol Sin"},{"key":"2026041507084599500_bib36","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.3390\/cancers16112027","article-title":"Landscape of endometrial cancer: molecular mechanisms, biomarkers, and target therapy","volume":"16","author":"Bostan","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026041507084599500_bib37","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026041507084599500_bib38","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jhep.2017.10.028","article-title":"Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma","volume":"68","author":"Hu","year":"2018","journal-title":"J Hepatol"},{"key":"2026041507084599500_bib39","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-12-0662","article-title":"The PI3K\/AKT\/mTOR pathway as a therapeutic target in endometrial cancer","volume":"18","author":"Slomovitz","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2026041507084599500_bib40","doi-asserted-by":"crossref","first-page":"175586","DOI":"10.1016\/j.ejphar.2023.175586","article-title":"The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF","volume":"949","author":"Ghalehbandi","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"2026041507084599500_bib41","doi-asserted-by":"crossref","first-page":"580971","DOI":"10.1155\/2010\/580971","article-title":"Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management","volume":"2010","author":"Seeber","year":"2010","journal-title":"Obstet Gynecol Int"},{"key":"2026041507084599500_bib42","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1200\/JCO.21.02506","article-title":"TP53 sequencing and p53 immunohistochemistry predict outcomes when bevacizumab is added to frontline chemotherapy in endometrial cancer: an NRG Oncology\/Gynecologic Oncology Group Study","volume":"40","author":"Thiel","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026041507084599500_bib43","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/ijc.35203","article-title":"TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: results of the MITO16A\/MaNGO OV-2 study","volume":"156","author":"Bignotti","year":"2025","journal-title":"Int J Cancer"},{"key":"2026041507084599500_bib44","first-page":"79","article-title":"Novel molecular targets in endometrial cancer: mechanisms and perspectives for therapy","volume":"18","author":"Soberanis Pina","year":"2024","journal-title":"Biologics"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0634\/3755178\/crc-25-0634.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/4\/832\/3770012\/crc-25-0634.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/4\/832\/3770012\/crc-25-0634.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:09:03Z","timestamp":1776251343000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/4\/832\/783614\/Preclinical-Combination-Targeting-VEGF-and-PI3K-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0634","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.32704970","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704991","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705036","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705003","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705048","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705015","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705027","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704985","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704976","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704964","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704997","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705009","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704958","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705030","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705042","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32705021","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8542097","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}